I’m going to need you to read this one twice. The University of Colorado Anschutz Gates Institute just received FDA IND clearance for a CD64-targeted CAR T-cell therapy for relapsed or refractory acute myeloid leukemia — and they built the entire thing in-house. No pharma partner. No licensing deal. No CRO handoff. From target discovery to IND filing, all under one academic roof.

That’s a first in the United States. And frankly, it should make a few biotech CEOs uncomfortable.

The target itself is fascinating. CD64 was identified in Craig Jordan’s lab as a marker expressed on leukemia cells that specifically evade existing treatments — the cells that slip through the cracks of current AML therapies. M. Eric Kohler engineered the CAR-T construct, and Haley Simpson handled preclinical optimization. The Phase 1 first-in-human trial in adult AML patients is slated to begin this summer.

Here’s why this matters beyond the novelty factor: AML is one of the hardest cancers to crack with cell therapy. Unlike B-cell malignancies where CD19 gives you a clean shot, AML targets tend to overlap with healthy myeloid cells. CD64 as a target suggests these researchers found something that distinguishes the treatment-resistant leukemia population specifically — and that’s the kind of biological insight that usually takes a well-funded biotech years and tens of millions to arrive at.

The broader signal here is about the evolving role of academic medicine in drug development. We’ve seen university labs contribute targets and early science for decades, but the full pipeline — discovery, engineering, preclinical, IND — staying in academic hands? That’s new. And it raises an interesting question for industry: if a university can do this, what exactly is the premium you’re paying for?

No data yet, obviously. This is IND clearance, not efficacy. But the model itself is worth watching closely — especially if the Phase 1 delivers even modest signs of activity in a disease that desperately needs new options.